Bibliography
Found 43 results
Filters: Keyword is Viral Load [Clear All Filters]
Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology. 2015 ;84(3):241-50.
Antiretroviral therapy reduces neurodegeneration in HIV infection. AIDS. 2015 ;29(3):323-30.
. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 ;82(23):2055-62.
Better executive function is independently associated with full HIV suppression during combination therapy. AIDS. 2019 ;33(15):2309-2316.
. Brain and liver pathology, amyloid deposition, and interferon responses among older HIV-positive patients in the late HAART era. BMC Infect Dis. 2017 ;17(1):151.
. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011 ;25(14):1747-51.
Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment. Journal of NeuroVirology [Internet]. 2006 ;12(3):178-89. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16877299
Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment. J Neuroinflammation. 2017 ;14(1):72.
Cerebrospinal fluid (CSF) biomarkers of iron status are associated with CSF viral load, antiretroviral therapy, and demographic factors in HIV-infected adults. Fluids Barriers CNS. 2017 ;14(1):11.
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011 ;17(3):248-57.
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol. 2010 ;67(5):552-8.
Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV. 2019 ;6(7):e456-e462.
Crack cocaine: effect modifier of RNA viral load and CD4 count in HIV infected African American women. Frontiers in Bioscience: A Journal and Virtual Library [Internet]. 2007 ;12:1488-95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17127396
. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother. 2011 ;66(2):354-7.
Elevated brain monoamine oxidase activity in SIV- and HIV-associated neurological disease. J Infect Dis. 2014 ;210(6):904-12.
. Emerging Patterns in HIV-1 gp120 Variable Domains in Anatomical Tissues in the Absence of a Plasma Viral Load. AIDS Res Hum Retroviruses. 2019 ;35(6):588-596.
. Eradication of HIV from Tissue Reservoirs: Challenges for the Cure. AIDS Res Hum Retroviruses. 2018 ;34(1):3-8.
. Evidence of the innate antiviral and neuroprotective properties of progranulin. PLoS One. 2014 ;9(5):e98184.
. Factors related to HIV-associated neurocognitive impairment differ with age. J Neurovirol. 2015 ;21(1):56-65.
. Frontline Science: CXCR7 mediates CD14CD16 monocyte transmigration across the blood brain barrier: a potential therapeutic target for NeuroAIDS. J Leukoc Biol. 2017 ;102(5):1173-1185.
. Gp120 in the pathogenesis of human immunodeficiency virus-associated pain. Ann Neurol. 2014 ;75(6):837-50.
Higher Anti-Cytomegalovirus Immunoglobulin G Concentrations Are Associated With Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy. Clin Infect Dis. 2018 ;67(5):770-777.
HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads. J Virol. 2016 ;90(20):8968-83.
HIV Maintains an Evolving and Dispersed Population in Multiple Tissues during Suppressive Combined Antiretroviral Therapy in Individuals with Cancer. J Virol. 2016 ;90(20):8984-93.
HIV-1 RNA concentration and cognitive performance in a cohort of HIV-positive people. AIDS (London, England) [Internet]. 2007 ;21:1415-22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17589187
.